Certain applications just canโt afford hallucinations. Scaled Cognition is so far the best answer I have seen. Best customer support solution I have seen.
We're excited to announce our $100M Series A led by @vkhosla & @khoslaventures.
@roth_dan & @profdanklein founded Scaled Cognition to solve the most important problem in AI, reliability.
Learn more: https://t.co/O8opdPzrQs
Today I'm publishing a new essay, Policy on the AI Exponential. AI is progressing extremely fastโmuch faster than the policy process was built to handle. The essay lays out where I think the technology is now, and the action needed to close the gap: https://t.co/Lh6PWae178
At 19 years old Mirra Andreeva is a major champion and itโs all thanks to Mirra. Mirra who put in the work, Mirra who battled for every point, Mirra who believed in Mirra.
Many thanks, Mirra.
The Demis Hassabis HUGE* Conversation (in full)
00:00 What is the hardest problem AI has already solved?
12:30 What is the cutting edge of drug discovery with AI?
21:53 Why did Demis say he โwould have left AI in the lab longerโ?
43:09 How should militaries use AI?
50:13 What can humans do that AI won't?
58:17 What does Demis Hassabis want his legacy to be?
(And 1:04:40 Can I beat Demis at Jenga?)
Recorded March 5, 2026 in London.
$750M upfront. $300M in milestones. $1.05B ceiling.
That's what Roche just paid for PathAI.
It is a 271-person Boston startup that was founded in 2016.
Here's why that number makes complete sense to me.
PathAI raised $255M across 6 rounds over 9 years.
Investors put in $255M, and Roche's check starts at $750M.
That's a 3x return on total capital raised before the $300M milestones even kick in.
But the real story isn't the exit multiple. It's how Roche got here.
2016 ..PathAI was founded. It builds an AI that reads cancer tissue slides.
Models trained on 15 million+ annotations, which is a huge number, btw.
2021.. Roche doesn't acquire them. Roche partners with them and runs PathAI's models inside actual drug trials, where they watch how it works in their own pipeline.
2024.. Partnership expands and builds FDA-grade companion diagnostic algorithms together.
PathAI is now embedded inside Roche's clinical infrastructure.
2026.. Roche buys them for $750M.
5 years of proof before the check is cleared.
Now, what does Roche actually own in my view?
An AI that tells oncologists which patients qualify for which cancer drugs, running in 160 countries. Across 600M+ diagnostic tests every year.
Interestingly, PathAI's models don't go to market. They go everywhere Roche already is.
Most acquirers write a check first and figure out the integration later.
Whereas Roche ran a 5-year pilot, proved every assumption, then bought certainty.
That's not M&A. That's the smartest structured acquisition I've seen in a long time.
If you're building in vertical AI, this is a great exit playbook.
Partner with your buyer first. Make yourself impossible to unplug.
Then negotiate from proof, not pitch decks.
Are you building something that becomes infrastructure, or something that stays a product?
Jannik Sinner can do it all. 6 consecutive titles, a career Golden Masters, and a new record set on home soil. This isn't just history โ it's his story in the making.
JUNE 2028.
The S&P is down 38% from its highs. Unemployment just printed 10.2%. Private credit is unraveling. Prime mortgages are cracking. AI didnโt disappoint. It exceeded every expectation.
What happened?โโโโโโโโโโโโโโโโ
https://t.co/JzzwCrbJgS
The Adolescence of Technology: an essay on the risks posed by powerful AI to national security, economies and democracyโand how we can defend against them: https://t.co/0phIiJjrmz